Revelation Biosciences, Inc. (REVB)
REVB Stock Price Chart
Explore Revelation Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze REVB price movements and trends.
REVB Company Profile
Discover essential business fundamentals and corporate details for Revelation Biosciences, Inc. (REVB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Nov 2020
Employees
8.00
Website
https://www.revbiosciences.comCEO
James M. Rolke
Description
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
REVB Financial Timeline
Browse a chronological timeline of Revelation Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 14 Nov 2025
EPS estimate is -$1.59.
Earnings released on 7 Aug 2025
EPS came in at -$7.01 falling short of the estimated -$4.46 by -57.17%.
Stock split effective on 7 Jul 2025
Shares were split 1 : 3 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 May 2025
EPS came in at -$6.33 surpassing the estimated -$20.64 by +69.33%.
Earnings released on 6 Mar 2025
EPS came in at -$4.98 falling short of the estimated -$3.20 by -55.63%.
Stock split effective on 28 Jan 2025
Shares were split 1 : 16 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Nov 2024
EPS came in at -$13.44 surpassing the estimated -$45.44 by +70.42%.
Earnings released on 9 Aug 2024
EPS came in at -$24.64 surpassing the estimated -$28.96 by +14.92%.
Earnings released on 10 May 2024
EPS came in at -$39.36 surpassing the estimated -$86.24 by +54.36%.
Earnings released on 22 Mar 2024
EPS came in at -$133.28 surpassing the estimated -$175.04 by +23.86%, while revenue for the quarter reached $37.57K .
Stock split effective on 25 Jan 2024
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Nov 2023
EPS came in at -$197.00 falling short of the estimated -$144.14 by -36.67%.
Earnings released on 11 Aug 2023
EPS came in at -$120.12 surpassing the estimated -$158.56 by +24.24%.
Earnings released on 22 May 2023
EPS came in at -$245.05 surpassing the estimated -$312.31 by +21.54%.
Earnings released on 30 Mar 2023
EPS came in at -$850.45 falling short of the estimated -$840.84 by -1.14%.
Stock split effective on 1 Feb 2023
Shares were split 1 : 35 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Nov 2022
EPS came in at -$1.01K surpassing the estimated -$1.51K by +33.33%.
Earnings released on 15 Aug 2022
EPS came in at -$2.02K surpassing the estimated -$2.35K by +14.29%.
Earnings released on 16 May 2022
EPS came in at -$16.45 falling short of the estimated -$4.90 by -235.71%.
Earnings released on 15 Apr 2022
EPS came in at -$486.32 .
Earnings released on 29 Oct 2021
EPS came in at -$351.38 .
Earnings released on 23 Aug 2021
EPS came in at -$285.03 .
Earnings released on 22 Jun 2021
EPS came in at -$301.52 .
Earnings released on 16 Jun 2021
EPS came in at -$334.06 .
Earnings released on 16 Nov 2020
EPS came in at -$0.10 .
REVB Stock Performance
Access detailed REVB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.